Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2017

Segment Reporting

Schedule of financial information by reporting segment

	Three Months Ended
	March 31,
	2017		2016
	(in thousands)
Net revenues:
Finished pharmaceutical products	$	55,934	$	58,554
API		736		812
Total net revenues		56,670		59,366
Gross profit:
Finished pharmaceutical products		24,310		25,824
API		(1,482)		(922)
Total gross profit		22,828		24,902
Operating expenses		21,424		20,827
Income from operations		1,404		4,075
Non-operating income (expenses)		100		(259)
Income before income taxes	$	1,504	$	3,816

Schedule of net revenues in the finished pharmaceutical products segment

	Three Months Ended
	March 31,
	2017		2016
	(in thousands)
Finished pharmaceutical products net revenues:
Enoxaparin	$	10,410	$	18,358
Naloxone		10,939		10,254
Epinephrine		9,574		4,392
Lidocaine		8,289		9,908
Phytonadione		7,886		6,126
Other finished pharmaceutical products		8,836		9,516
Total finished pharmaceutical products net revenues	$	55,934	$	58,554

Schedule of net revenues and carrying values of long-lived assets by geographic region

	Net Revenue				Long-Lived Assets
	Three Months Ended
	March 31,				March 31,		December 31,
	2017		2016		2017		2016
	(in thousands)
United States	$	55,930	$	58,538	$	106,352	$	104,110
China		—		—		36,034		35,085
France		740		828		14,914		13,659
United Kingdom		—		—		89		90
Total	$	56,670	$	59,366	$	157,389	$	152,944